Ixabepilone

From Anvita Health Wiki

Contents 1 Indications 2 Contraindications 3 Dosage 4 Monitor 5 Adverse-effects 6 Mechanism-of-action 7 More General Terms 8 References

Indications

• metastatic breast cancer

Contraindications

• hepatic dysfunction ( serum ALT or serum AST > 2.5x upper limit of normal, or serum bilirubin elevated)

Dosage

• dosage adjustment for serum AST or serum ALT elevation

Monitor

• serum ALT, serum AST, & serum bilirubin at baseline & as needed during treatment (see contraindications) [5]

Adverse-effects

• fatigue (13%)
• myalgia (8%)
• mucositis (6%)
• sensory neuropathy (28%)
• motor neuropathy (1/23 patients)

Mechanism-of-action

• microtubule stabilization

• interaction with microtubules differs from taxanes

• induces apoptosis

More General Terms

• antineoplastic agent (chemotherapeutic agent)

References

1. Perez EA et al, Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007, 25:3407 PMID: [1]
2. Thomas E et al, Phase II clinical trial of ixbepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007, 25:3399 PMID: [2]
3. Dendeluri N et al Phase II trial of ixabepilone, en epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes J Clin Oncol 2007, 25:3421 PMID: [3]
4. Roche H et al, Phase II clinical trial of ixbepilone (BMS-247550), an epothilone B analog, as first line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007, 25:3415 PMID: [4]
5. Prescriber's Letter 17(7): 2010 Recommended Lab Monitoring for Common Medications Liver Function Test Scheduling Detail-Document#: [5] (subscription needed) [6]

ixabepilone (BMS-247550)